D. Thrilled to share this work from my former group at Genentech, reporting on a new class of peptide agonists that modulate. Beitrag von Rami Hannoush, Ph. Biomarker interview with Rami Hannoush, Ph. D. It is tightly controlled by a set of enzymes which catalyze the covalent attachment of fatty. Synthetic protein lipidation. Rami N. interim CEO and co-founder of EpiBiologics and venture partner at Versant Ventures. “We would like to thank Rami Hannoush for his leadership as co-founder and interim CEO and look forward to an exciting next stage of growth for EpiBiologics under Ann’s leadership. ’s Post Rami Hannoush, Ph. Epub 2021 Dec 10. Cunningham5,* 1Department of Structural Biology 2Center for Advanced Light Microscopy 3Department of Protein Chemistry 4Department of Discovery Oncology 5Department of Early Discovery Biochemistry Genentech, Inc. Rami Hannoush, Ph. Fatty acylation of proteins is a versatile co-translational or post-translational modification that plays a key role in human. The . D. Rami Hannoush is a venture partner operating across San Diego and the San Francisco Bay Area. Hannoush is a general partner at Mubadala Capital, the financial investment arm of the Sovereign Wealth Fund Mubadala. ’s Post Rami Hannoush, Ph. Rami. Rami N Hannoush Adjunct Professor, Chemical and Systems Biology Operations Print Profile Email Profile Bio Bio Professional Contact. Hannoush joined the Early Discovery Biochemistry department at Genentech in 2006 after completing his postdoctoral fellowship at Harvard and his Ph. Back Submit. degree at McGill University. Rami Hannoush, Genentech, South San Francisco, USA 5:25 pm General Discussion, Day 2 Wrap-Up 6:00 pm Reception, dinner . interim CEO and co-founder of EpiBiologics and venture partner at Versant Ventures. ’s Post Rami Hannoush, Ph. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 4mo Edited Report this post At last, after 43 years since the discovery of the Wnt gene, the structure of the ternary Wnt – Frizzled – LRP6 signaling complex is reported here, and it provides a blueprint that. , for the launch of [email protected]. Rami Hannoush: Chemical tools to perturb and image Wnt signaling: Danica Galonic Fujimori: 3/15/12: Harmit Malik, Fred Hutchinson Cancer Center: Genetic conflicts: the usual suspects and beyond: John Gross: 4/5/12: Ian Wilson, Scripps: Broad neutralization of HIV and influenza viruses: Bob Stroud:It started with a cup of coffee and a slow burning desire to go early and long in the biotech creation business. D. He focuses on early-stage biotechnology investments, and also leads the firm’s efforts in life sciences company creation. Congratulations to our own Rami Hannoush, Principal Scientist, Early Discovery Biochemistry, for being one of ten to receive the U. Sponsors and Exhibitors. Hannoush, Rami Nabil; Contributors. Taipale, P. . D. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 1w EditedRami Hannoush; Found 5 results for your query: Rami Hannoush in the United States of America. interim CEO and co-founder of EpiBiologics and venture partner at Versant Ventures. Rami Hannoush, Ph. J Pharm Sci 2022 07 10;111(7):1896-1910. S. Here, we determined a crystal structure of human FZD7 CRD unexpectedly bound to a 24-carbon fatty acid. Rami Hannoush, Ph. Alanna Schepartz, The University of California, Berkeley. Palmitate can either be added to. Scroll Top. … | 79 comments on LinkedInRami Hannoush, Ph. Supplementary Figure 1 S5 . Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 3mo Edited Report this post At last, after 43 years since the discovery of the Wnt gene, the structure of the ternary Wnt – Frizzled – LRP6 signaling complex is reported here, and it provides a blueprint that. Yet, how different Wnts achieve various levels of signaling activation through distinct domains on LRP6 remains [email protected]@gene. D. … | 79 comments on LinkedInAt last, after 43 years since the discovery of the Wnt gene, the structure of the ternary Wnt – Frizzled – LRP6 signaling complex is reported here, and it…Publicação de Rami Hannoush, Ph. Genentech Inc. Conference Description. 11mo Report this comment Report Report. D. D. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 1y EditedRami Hannoush, Ph. D. ’s Post Rami Hannoush, Ph. Great chat with Ron Leuty from San Francisco Business Times to share our story on building EpiBiologics #companybuilding #degradation | 28 comments on LinkedInComing out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. Join to view full profile. hannoush. Healthcare VC | Life sciences company creation 6dRami Hannoush, Ph. … | 76 comments on LinkedInComing out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. Biomarker interview with Rami Hannoush, Ph. D. ’s Post Rami Hannoush, Ph. According to LinkedIn Rami Hannoush started working on 2006, then the employee has changed 9 companies and 12 jobs. Expand search. According to LinkedIn Rami Hannoush started working on 2006, then the employee has changed 9 companies and 12 jobs. Auron Therapeutics, a Newton, Mass. D. D. The small size of the chemical tag is meant to minimize interference with fatty acyltransferase substrate recognition and catalytic efficiency (Hannoush, 2015, Hannoush and Arenas-Ramirez, 2009). I had the pleasure to join Rob Faulkner and Soo. Rami Hannoush serves as Venture Partner at Versant Ventures. com. ’s Post Rami Hannoush, Ph. D. منشور Rami Hannoush, Ph. D. , 1 DNA Way, South San Francisco, CA 94080, USA. Healthcare VC | Life sciences company creation. D. -based biopharmaceutical company focused on developing therapies that target dysregulated differentiation and cellular. D. Rami Hannoush, EpiBiologics is building a protein degradation platform that targets membrane and extracellular proteins. At last, after 43 years since the discovery of the Wnt gene, the structure of the ternary Wnt – Frizzled – LRP6 signaling complex is reported here, and it…Rami Hannoush, Ph. , 1 DNA Way, South San Francisco, CA 94080, USA. Rami N. Recent News and Activity. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 2mo Report this post Report Report. D. Inventors: Eric Bourhis, Tim Cao, Rick Carano, Andrea Cochran, Mike Costa, Venita DeAlmeida, James Ernst, Yan Gong, Rami Hannoush, Paul Polakis, Bonnee Rubinfeld, Mark Solloway, Yan Wu METHODS AND COMPOSITIONS FOR MODULATING THE Wnt PATHWAY Protein palmitoylation plays diverse roles in regulating the trafficking, stability, and activity of cellular proteins. Rami Hannoush Ph. This button displays the currently selected search [email protected] Hannoush, Ph. Lotte Simonsen, Novo Nordisk. Hannoush, Rami Nabil; Contributors. Patrick Sexton, Monash University. Rami N. Healthcare VC | Life sciences company creation 6dRami Hannoush, Ph. Recent News. , as Chief Data Officer,. Rami Hannoush General Partner, Mubadala Capital | Life sciences company creation | Chief Scientific Officer 1y EditedRami Hannoush, Ph. Alanna Schepartz, The University of California, Berkeley. D. Rami Hannoush, Ph. … | 77 comments on LinkedInRami N. Rami Hannoush, Ph. rami@gene. D. EpiBiologics - a biotechnology company advancing a next-generation antibody-based protein degradation platform and pipeline for membrane and extracellular drug targets - recently announced the company brought the total series A round to $73 million with the addition of $23 million from new investors Digitalis Ventures, Taiho. 19th Ave New York, NY 95822, USA. … | 76 comments on LinkedInComing out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. It has been an incredible journey building this company. interim CEO and co-founder of EpiBiologics and venture partner at Versant Ventures. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 6mo Edited Report this post. . chembiol. Jobs. hannoush. PMID: 31152407 DOI: 10. … | 76 comments on LinkedInComing out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 1mo Report this post Report Report. Marianne Mertens, [email protected]. Lee-Karlon served as. ’s Post Rami Hannoush, Ph. Stablix is pioneering an entirely new field of targeted deubiquitination therapeutics (TDT) to bring transformative medicines to patients with unmet medical need. Mr. Coming out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. D. D. Genentech, McGill, Harvard, Versant Ventures. com. We cover his grad school/post-doc training in chemical biology, 15+ years as a group leader Genentech and. … | 80 comments on LinkedInRami Hannoush’s Post Rami Hannoush General Partner, Mubadala Capital | Life sciences company creation | Chief Scientific Officer 10mo Report this post. We are dedicated to bridging ideas from academia with the cutting edge in biotechnology and translation. … | 77 comments on LinkedInComing out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. Rami Hannoush is the co-founder, interim CEO and president of EpiBiologics. Schneider, National Cancer Institute – Center for Cancer Research. rami@gene. The authors would like to acknowledge Dr. Supplementary Text and Figures. 4 the Department of Early Discovery Biochemistry, Genentech, South San Francisco, California 94080, and hannoush. D. The Frizzled (FZD) 7 receptor (FZD7) is enriched in LGR5 + intestinal stem cells and plays a. ’s Post Rami Hannoush, Ph. Rami Hannoush, PhD. Shawn Zhang Karthik Nagapudi Mike Shen Joshua Lomeo Yuri Qin Aiden Zhu Purnendu Nayak Debby Chang Rami N Hannoush. There is no recent news or activity for this profile. … | 76 comments on LinkedInComing out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation [email protected] Hannoush, Ph. 19th Ave New York, NY 95822, USA. Expand search. View the profiles of professionals named. D. A. , Department of Protein Engineering, 1 DNA Way, South San Francisco, CA 94080, USA, hannoush. Rami Hannoush, Ph. , Partner at Mubadala Capital, and Dr. Drug Discovery & Development Oncology Wnt and Stem Cells Peptide Therapeutics. His current role includes leading interdisciplinary teams in lead discovery and research biology, with the overarching goal of developing therapeutics. Rami Hannoush, Ph. Coming out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. 1016/j. My group takes a genetic approach to studying signaling pathways relevant to human disease. Healthcare VC | Life sciences company creation 6 dComing out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. Simon Hansen 1 , Yingnan Zhang 1 , Sunhee Hwang 1 , Ahmad Nabhan 2 , Wanqing Li 1 , Jakob Fuhrmann 1 , Yvonne Kschonsak 3 , Lijuan Zhou 1 , Aaron H Nile 1 , Xinxin Gao 1 , Robert Piskol 3 , Felipe de Sousa E Melo 3 , Frederic J de Sauvage 3 , Rami N Hannoush 1 Contact Rami directly. Xinxin Gao 1 , Rami N Hannoush 1 Affiliation 1 Department of Early Discovery Biochemistry, Genentech, Inc. Rami Hannoush, Ph. rami@gene. Healthcare VC | Life sciences company creation | Former R&D leader, GenentechComing out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. D. Connect Hamed Alemohammad Greater Boston. Rami N. D. EpiBiologics - a biotechnology company advancing a next-generation antibody-based protein degradation platform and pipeline for membrane and extracellular drug targets - recently announced the company brought the total series A round to $73 million with the addition of $23 million from new investors Digitalis Ventures, Taiho Ventures, and existing investor Codon Capital. 120. D. D. D. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 1mo Edited Report this post Report Report. D. EpiBiologics is building a next-generation antibody-based protein degradation platform for membrane and extracellular drug targets. 11mo Report this comment Report Report. BSMB Spring meeting 2022: "Interactions between Lipids/derivatives and the ECM: pre-clinical and clinical relevance" Registration for BSMB members is FREE, £10 and £30 respectively for student. … | 79 comments on LinkedInRami Hannoush, Ph. Rami Hannoush, Ph. Materials availability This study did not generate new unique reagents. D. interim CEO and co-founder of EpiBiologics and venture partner at Versant Ventures. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 2mo Report this post Report Report. , Partner at Mubadala Capital, and Dr. Rami Hannoush, Ph. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 2mo Report this post Report Report. Rami Hannoush, Ph. D. Healthcare VC at Versant | Life sciences company creation | Former R&D leader, Genentech | Former CEO, EpiBiologics 1y. com). Rami Hannoush, Ph. D. … | 80 comments on LinkedInAt last, after 43 years since the discovery of the Wnt gene, the structure of the ternary Wnt – Frizzled – LRP6 signaling complex is reported here, and it…Fully funded PhD position in my group to investigate the mechanisms of cartilage regeneration Defining the molecular drivers of cartilage regeneration at…Biomarker interview with Rami Hannoush, Ph. Healthcare VC | Life sciences company creation 6dRami Hannoush, Ph. For info and…Biomarker sits down with Rami Hannoush, General Partner at Mubadala Capital Ventures. Patrick Sexton, Monash University. D. Coming out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. Rami Hannoush, education was also an escape. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 1mo Report this post Report Report. ’s Post Rami Hannoush, Ph. EpiBiologics develops antibody-based targeted therapies against. This button displays the currently selected search type. In 2021, when Genentech researcher and team leader Rami Hannoush was looking to leave his job at the South San Francisco biotechnology giant, an acquaintance reached out with a question. ” Prior to EpiBiologics, Dr. He most recently served as a general partner at Mubadala Capital, building the firm's healthcare platform in the. D. D. In an interview with BioPharma Dive: Biotech and Pharma news, our co-founders Jim Wells and Rami Hannoush discussed the company's origin and EpiBiologics' differentiated protein degradation approach. EpiBiologics’s CEO is Rami Hannoush Who are EpiBiologics key employees? Some of EpiBiologics key employees are Craig Lichtenstein Where is EpiBiologics located? EpiBiologics’s headquarters are located at 1900 Alameda De Las Pulgas Ste 250, San Mateo, California, 94403, United States How do I contact EpiBiologics? Rami Hannoush, Ph. EpiBiologics’s CEO is Rami Hannoush Who are EpiBiologics key employees? Some of EpiBiologics key employees are Craig Lichtenstein Where is EpiBiologics located? EpiBiologics’s headquarters are located at 1900 Alameda De Las Pulgas Ste 250, San Mateo, California, 94403, United States How do I contact. D. 1618293114 Abstract Frizzled (FZD) receptors mediate Wnt signaling in diverse processes ranging from bone growth to stem cell activity. rami@gene. “Dysregulation of normal cellular differentiation processes can alter normal cell biology leading to tumor formation and progression,” said Dr. The design of clickable fatty acid probes is based on the introduction of a small chemical tag (alkyne or azide) at the ω or methyl end of the fatty acid (Figure 2). Rami Hannoush, Ph. ’s Post Rami Hannoush, Ph. Electronic address: hannoush. Genentech Inc. com. 4d Edited. D. Back. Contact Email [email protected] Abstract Protein palmitoylation plays diverse roles in regulating the trafficking, stability, and activity of cellular proteins. , Partner at Mubadala Capital, and Dr. hannoush. Copy Link. 1016/j. com. View Rami Hannoush's record in Watertown, MA including current phone number, address, relatives, background check report, and property record with Whitepages. D. D. ’s Post Rami Hannoush, Ph. Rami Hannoush, co-founder and interim CEO of EpiBiologics, discusses the company’s platform technology, how its protein degradation approach expands the potential targets for its therapies; and. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO). com; PMID: 21964784 DOI: 10. Genentech veteran Rami Hannoush, UCSF professor Jim Wells team up to score $50M for protein degradation startup EpiBiologics - San Francisco Business TimesThere are 8 professionals named "Rami D", who use LinkedIn to exchange information, ideas, and opportunities. Rami Hannoush is a venture partner operating across San Diego and the San Francisco Bay Area. Eric Shiozaki: Casdin Capital — BrightEdge Fund — Arkin Bio Ventures — Apollo Health Ventures . Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 2mo Report this post Report Report. Rami Hannoush, Ph. Expand search. Healthcare VC | Life sciences company creation 6dRami Hannoush, Ph. Based on the protocol by Xinxin Gao and Rami N. Chief Operating Officer (650) -. He brings a unique blend of investment experience and deep drug discovery expertise to our company creation efforts. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 4mo Edited Report this post At last, after 43 years since the discovery of the Wnt gene, the structure of the ternary Wnt – Frizzled – LRP6 signaling complex is reported here, and it provides a blueprint that. Rami Hannoush, co-founder and interim CEO of EpiBiologics, discusses the company’s platform technology, how its protein degradation approach expands the potential targets for its therapies; and. Mubadala Capital Ventures General Partner Sep 2021. Last Funding Type Series A. ’s Post Rami Hannoush, Ph. Hannoush is a general partner at Mubadala Capital, the financial investment arm of the Sovereign Wealth Fund Mubadala. Burns, Irina N. Born on September 20th, 1976 (47 years old)Rami Hannoush, Ph. Genentech, McGill, Harvard, Versant Ventures. Question: Add details. Human OS cell lines (MNNG/HOS, MG-63, and U2-OS) were treated with increasing concentrations of dynasore or cisplatin, and then the cell. Jumi Shin, University of Toronto. San Mateo, CA. Biomarker interview with Rami Hannoush, Ph. The Hannoush group is focused on developing pharmacological strategies for targeting proteins and protein – protein interactions that are important in disease, with the aim of developing novel therapeutics and at the same time advancing their understanding of cellular molecular mechanisms. Rami Hannoush, Ph. 1038/s41589-018-0035-2 Abstract Regeneration of the adult intestinal epithelium is mediated by a pool of cycling stem cells, which are located at the base of the crypt, that express leucine-rich-repeat-containing. Much less common are ribonucleic acids based on 2',5'-phosphodiester linkages (2',5'-RNA). 1073/pnas. Courtesy of EpiBiologics. 3 Department of Early Discovery Biochemistry, Genentech, South San Francisco, CA 94080; hannoush. Healthcare VC | Life sciences company creation 6dTherapeutics. ’s Post Rami Hannoush, Ph. Schedule view. Rami Hannoush has been working as a General Partner | US Ventures for Mubadala for 456 days. Rami most recently served as a general partner at Mubadala Capital, building the firm’s healthcare platform in the U. teins generated by cancer genes, says Rami Hannoush, a chemical biologist at the biopharmaceutical company Genentech. Coming out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. Hannoush and Arenas-Ramirez, 2009; Martin and Cravatt, 2009) also showed efficient bioorthogonal labeling of fatty acyl-Wrapping up a 15-year discovery stint at Genentech back in the summer of 2021, Rami Hannoush was treated to a caffeine-fueled review of the latest work UCSF’s Jim Wells had been doing on protein degradation — one of the hottest fields in drug development. Rami Hannoush, PhD. “Jim and I have known each other for the past 15 years through Genentech collaborations. D. D. D. Rami Hannoush, EpiBiologics is building a protein degradation platform that targets membrane and extracellular proteins. When expanded it provides a list of search options that will switch the search inputs to match the. Rami N. D. Hannoush* and Natalia Arenas-Ramirez . interim CEO and co-founder of EpiBiologics and venture partner at Versant Ventures. . Rami Hannoush, Ph. com. Expand search. We cover Rami's new role at Versant, the founding story of. Rami Hannoush, Ph. … | 79 comments on LinkedInRami Hannoush, Ph. Recent work has focused. Rami Hannoush, Ph. CSB 243: Biotechnology and Development of Therapeutics (Autumn) Regeneration of the adult intestinal epithelium is mediated by a pool of cycling stem cells, which are located at the base of the crypt, that express leucine-rich-repeat-containing G-protein-coupled receptor 5 (LGR5). Rami Hannoush, Ph. ’s Post Rami Hannoush, Ph. San Mateo, CA. … | 77 comments on LinkedInRami Hannoush, Ph. 5W96, 5WBS. Rami Hannoush, Ph. Back. He brings a unique blend of investment experience and deep drug discovery expertise to our. We cover Rami's new role at. Healthcare VC | Life sciences company creation | Former R&D leader, Genentech 1mo Report this post Report Report. The acquaintance was Jim Wells, a professor at the University of California San Francisco who had helped found Genentech’s protein engineering department. ’s Post Rami Hannoush, Ph. interim CEO and co-founder of EpiBiologics and venture partner at Versant Ventures. D. , 1 DNA Way, South San Francisco, CA. ACS Chemical Biology editors highlight articles from Volume 4, Issue 7, and speak with authors Rami Hannoush and Domagoj Vucic. Antibody Engineering & Therapeutics is the largest forum for scientific exchange and networking in the fields of antibody engineering and therapeutics, immunobiology and next-generation bindersRami Hannoush, Ph. We cover Rami's new role at Versant, the founding story of. Its proprietary EpiTAC platform is a. Funds will also. Xinxin Gao, Xinxin Gao. ’s Post Rami Hannoush, Ph. Rami Hannoush. Back. Phone and address: 35 28Th Ave #300, San Mateo, CA 94403. Rami Hannoush, Ph. Symposium Sponsors. Citizen and Immigration Services (USCIS) 2019 Outstanding. D. , 1 DNA Way, South San Francisco, CA 94080, USA. … | 76 comments on LinkedInRami Hannoush, Ph. EpiBiologics Co-Founder. Citizen and Immigration Services 2019 Outstanding Americans by. has lived in San Mateo, CA Watertown, MA 1200 Massachusetts Ave, Cambridge, MA 02138 Foster City, CA. Hannoush has filed for patents to protect the following inventions. 2015 Oct:28:39-46. D. Search for more papers by this author Speakers – APS 2022. Department of Protein Engineering, Genentech, Inc. ’s Post Rami Hannoush, Ph. com. Healthcare VC | Life sciences company creation 6dRami Hannoush, Ph. Targeting the destruction of proteins, Peninsula biotech EpiBiologics raises $50M. Hannoush is an academic researcher from Genentech. Rami has 3 jobs listed on their profile. Coming out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. Joel P. I had the pleasure to join Rob Faulkner and Soo Romanoff on a. Name & Title Social Contact Info; Craig Lichtenstein. Here’s everything you need to know about […]Correspondence to Rami N Hannoush. Hannoush and Phil S. Adam Catherman for valuable discussions. , joined the Early Discovery Biochemistry department at Genentech in 2006 after completing his postdoctoral fellowship at Harvard and his Ph. rami@gene. D. Speakers – APS 2022. 1038/nchembio. ’s Post Rami Hannoush, Ph. We cover Rami's new role at Versant, the founding story of. D. D. Professor Nagy Habib is Head of Surgery at the Hammersmith Campus of Imperial College London and also a serial founder and entrepreneur of life sciences ventures. 5 From the Section of Receptor Biology and Signaling, Department of Physiology and Pharmacology, Karolinska Institutet, S-171 77 Stockholm, Sweden, the Faculty of Science, Institute of Experimental Biology, Masaryk. PMID: 29632413 DOI: 10. com. … | 76 comments on LinkedInComing out of stealth mode, I'm thrilled to announce the unveiling of EpiBiologics, a biotech company advancing a next-generation protein degradation platform. Healthcare VC | Life sciences company creation 6 TageThank you Ayman, Alaa, and Rami for your trust and support! Could not have asked for better partners. Connect Alison Symington Strategic expertise in bringing innovation in the life sciences. D. Lee-Karlon served as. San Mateo, California, United States 4K followers 500+ connections See your mutual connections Join to follow Versant Ventures Harvard University. --,,. 1392 Abstract Wnts are secreted palmitoylated glycoproteins that are important in embryonic development and human cancers. Founded in 2022 and led by CEO Dr. D. This past Saturday, the Class of 2023…Biomarker interview with Rami Hannoush, Ph. . He also recently joined Versant Ventures (as a venture partner) where he. Rami Hannoush is a co-founder, President and interim CEO of EpiBiologics.